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Acquiring therapy resistance is oneof themajor obstacles in the treatment of patientswith cancer. Thediscovery of the
cancer stem cell (CSC)–specific drug salinomycin raised hope for improved treatment options by targeting therapy-
refractory CSCs and mesenchymal cancer cells. However, the occurrence of an acquired salinomycin resistance in
tumor cells remains elusive. To study the formation of salinomycin resistance, mesenchymal breast cancer cells were
sequentially treated with salinomycin in an in vitro cell culture assay, and the resulting differences in gene expression
and salinomycin susceptibility were analyzed. We demonstrated that long-term salinomycin treatment of
mesenchymal cancer cells resulted in salinomycin-resistant cells with elevated levels of epithelial markers, such as
E-cadherin andmiR-200c, a decreasedmigratory capability, and a higher susceptibility to the classic chemotherapeutic
drug doxorubicin. The formation of salinomycin resistance through the acquisition of epithelial traits was further
validated by inducingmesenchymal-epithelial transition through an overexpression of miR-200c. The transition from a
mesenchymal to a more epithelial-like phenotype of salinomycin-treated tumor cells was moreover confirmed in vivo,
using syngeneic and, for the first time, transgenic mouse tumor models. These results suggest that the acquisition of
salinomycin resistance through the clonal selection of epithelial-like cancer cells could become exploited for improved
cancer therapies by antagonizing the tumor-progressive effects of epithelial-mesenchymal transition.
Translational Oncology (2014) 7, 702–711(28/IND/P32). V.K.U. was supported by a grant from the Deutsche Krebshilfe
Foundation (109081). Conflict of interest: The authors declare no conflict of interest.
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The acquisition of chemoresistance represents one of the major
obstacles in cancer treatment. Albeit early detection methods improved
and novel treatment options emerged, resistance formation to
chemotherapeutics remains an enormous challenge for cancer therapy.
In breast cancer, 30% of all patients with breast cancer suffer a relapse
associated with metastasis and chemoresistance. The response rates for
classic chemotherapy including anthracyclines and taxanes drop to only
20% to 30% on disease progression, even though the response rates for
first-line chemotherapy are up to 70%. Several resistance mechanisms,
such as the up-regulation of ATP binding cassette transporters and the
overexpression and constitutive activity of growth factor receptors or
certain other proteins and enzymes like β-tubulin III and thioredoxin
[1–4], have been identified over the last years. In addition, recent
findings on intratumoral heterogeneity [5–7] suggest that clonal
evolution and plasticity are important drivers of the long-term resistance
formation to chemotherapy. With regard to this, cancer stem cells
(CSCs) became important targets of therapeutic approaches as they give
rise to resistant subpopulations and thus are assumed to be one of the
major causes of relapse and therapy resistance. Gupta et al. have found
salinomycin to be a selective inhibitor of CSC, being 100-fold more
effective than paclitaxel, a commonly used chemotherapeutic breast
cancer drug [8]. Subsequent studies in a variety of different cancer types
including breast, blood, lung, pancreas, and colon have revealed diverse
mechanisms of salinomycin action against CSC resulting in apoptosis
and cell death [9–12]. Interestingly, in several recent studies,
salinomycin has been reported to induce apoptosis in cisplatin-resistant
cancer cells [13–15], to overcome ATP binding cassette transporter–
mediated drug resistance in leukemia cells [16], and to sensitize cancer
cells to different chemotherapeutic drugs [17,18], hence circumventing
the resistance to classic chemotherapy. Therefore, treatment with
salinomycin in addition to classic cancer therapy could greatly improve
the prognosis of patients with cancer. Several case studies applying
salinomycin in a clinical setting revealed beneficial effects in patients
with exhausted therapy options [9]. Because of these promising results,
it is of great interest to investigate resistance formation to salinomycin
treatment as the occurrence and the potential underlying mechanisms
of an acquired salinomycin resistance in cancer cells remain elusive.
In this study, we sought to investigate the resistance formation to
long-term sequential salinomycin treatment in an in vitro cell culture
assay. We found that repeated salinomycin treatment resulted in a
clonal selection of cells displaying more epithelial traits and increased
resistance to salinomycin. Of note, in syngeneic and transgenic
mouse tumor models, we also observed the selection of epithelial-like
cell clones.Materials and Methods
Reagents
These primary antibodies against the following proteins were used:
actin (I-19) (SC-1616; Santa Cruz Biotechnology, Dallas, Texas) for
Western blot (WB); vimentin (D21H3) XP (#5741; Cell Signaling
Technology, Boston, Massachusetts) for WB and in vivo immuno-
histochemistry (IHC)/immunofluorescence (IF); E-cadherin
(24E10) (#3195; Cell Signaling Technology) for WB and in vivo
IHC/IF; E-cadherin (DECMA-1) (ab11512; Abcam, Cambridge,
UK) for in vitro IF; vimentin (V9) (SC-6260, Santa Cruz
Biotechnology) for in vitro IF. Salinomycin (S6201) was obtained
from Sigma-Aldrich, Munich, Germany.Cell Culture
The breast (BT-474, MCF-7, MDA-MB-231, MDA-MB-436, and
4T1) and lung (NCI-H1299 and Lewis lung carcinoma) cancer cell
lines were cultivated according to the supplier’s instructions (ATCC).
Transfections
For miR-200c overexpression experiments, cells were transfected
with either Pre-miR miRNA Precursor of hsa-miR-200c (pre-
miR-200c; Ambion) or Pre-miR miRNA Negative Control (control;
Ambion) using Lipofectamine 2000 (Invitrogen,Darmstadt, Germany)
according to the manufacturer’s protocol.
Quantitative Reverse Transcription–Polymerase Chain Reaction
Total RNA was isolated with the miRCURY RNA Isolation Kit
(Exiqon, Vedbaek, Denmark) according to the manufacturer’s instruc-
tions. miRNA or mRNA was reversely transcribed and subjected to
quantitative reverse transcription–polymerase chain reaction (RT-PCR) as
described previously [19]. All experiments were done in triplicate, and the
following primers and hydrolysis probes (Roche, Penzberg, Germany)
were used: E-cadherin (hsa), UPL Probe #35, left primer: CCCGGGA-
CAACGTTTATTAC, right primer: GCTGGCTCAAGT-
CAAAGTCC; vimentin (hsa): UPL Probe #56, left primer:
GTTTCCCCTAAACCGCTAGG, right primer: AGCGAGAGTGG-
CAGAGGA; zeb2 (hsa): UPL Probe #68, left primer: AAGCCAGGGA-
CAGATCAGC, right primer: CCACACTCTGTGCATTTGAACT;
Glycerinaldehyd-3-phosphat-Dehydrogenase (GAPDH) (hsa), UPL
Probe #60, left primer: AGCCACATCGCTCAGACAC, right primer:
GCCCAATACGACCAAATCC; E-cadherin (mmu): UPL Probe
#18, left primer: ATCCTCGCCCTGCTGATT, right primer:
ACCACCGTTCTCCTCCGTA; vimentin (mmu): UPL Probe
#79, left primer: TGCGCCAGCAGTATGAAA, right primer:
GCCTCAGAGAGGTCAGCAAA; zeb2 (mmu): UPL Probe #42,
left primer: CCAGAGGAAACAAGGATTTCAG, right primer:
AGGCCTGACATGTAGTCTTGTG; GAPDH (mmu): Universal
ProbeLibrary Mouse GAPD Gene Assay (Roche); miR-200c stem
loop primer (hsa and mmu): GTTGGCTCTGGTGC-AGGGTCC
GAGGTATTCGCACCAGAGCCAACTCCATC; miR-200c for-
ward primer: GCGTAATACTGCCGGGTAAT; universal reverse
primer: GTGCAGGGTCCGAGGT.
Cell Lysis and Immunoblot Analysis
WB experiments were performed as described previously [19]
using the respective antibodies from the Reagents section.
Cell Viability Assay
For cytotoxicity experiments, cells were seeded on 96-well plates at
a density of 5000 cells per well. After 24 hours, cells were incubated
with the respective drugs for 72 hours unless otherwise indicated.
Subsequently, the CellTiter-Glo (Promega, Mannheim, Germany)
assay was performed according to the manufacturer’s protocol. Cell
viability was normalized to the respective mock-treated control cells
and presented as percent of control. Half maximal inhibitory
concentration (IC50) values for salinomycin were obtained from
several different drug concentrations using GraphPad Prism software
for analysis. All experiments were done in triplicate.
Long-Term In Vitro Salinomycin Treatment
MDA-MB-436 cells received a long-term pulsed salinomycin
treatment similarly as it has been described previously [19]. Briefly,
MDA-MB-436 cells were treated with 50 nM salinomycin for
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salinomycin was removed and replaced by fresh medium. As soon as cells
recovered, they were treated again with salinomycin. After the indicated
treatment cycles, the recovered salinomycin-treated cells were harvested
for RNA isolation, cell lysis (protein), cytotoxicity, and migration assays.
Boyden Chamber Migration Assay
Transwells (8 μm pore size; Millipore, Darmstadt, Germany) were
placed in 24-well plates containing 10% fetal calf serum inmedium.Cells
were suspended in 250μl of serum-freemedium, added to the top of each
chamber and incubated for 18 hours. Subsequently, chambers were
washed and cells were removed from the upper side of the chamber with a
cotton swab. Migrated cells were fixed and stained using the cell stain
solution (Chemicon International, Darmstadt, Germany). The average
number ofmigrated cells from15 representative fields (three replicates per
condition) was counted under a phase contrast microscope. Microscopic
pictures (phase contrast) show representative stained transwells.
Time-Lapse Microscopy
Time-lapse microscopy was performed using a live-cell imaging setup
consisting of a microscope (Carl Zeiss MicroImaging, Jena, Germany)
equippedwith a Pln Apo 10×/0.45DICII objective, amotorized scanning
table, and a stage incubator at 37°C with or without CO2. Images were
captured with an AxioCamMRRev3 camera using the Axiovision Rel 4.8
software for microscope control and data acquisition. Indicated cells were
seeded in 24-well plates at a density of 50% to 70% and grown overnight.
The images were captured every 15 minutes for 72 hours. Each reading
was performed in triplicate. Ten randomcells perwell, i.e., 30 randomcells
per condition, weremanually tracked using ImageJ [20], and the data were
analyzed using the “chemotaxis and migration tool” plugin for ImageJ.
Tumor Cell Co-Culture
MCF-7 and MDA-MB-436 cells were co-cultured in Dulbecco's
modified Eagle's medium/Leibovtiz’s L-15 medium (1:1). For
cytotoxicity assays, 5000 co-cultured cells per well were seeded in a
96-well plate and incubated overnight. Subsequently, cells were treated
with 0.25 μM salinomycin, 0.25 μM doxorubicin, or the combination
of 0.25μMsalinomycin and 0.25μMdoxorubicin for 72 hours. For IF,
cells were seeded on coverslips at a density of 50% to 60%.
In Vitro IF
Cells were seeded on coverslips. At a confluency of 50% to 60%, cells
were fixed with 4% paraformaldehyde and blocked with 10% fetal calf
serum, 1% gelatin, and 0.05%Triton X-100. After permeabilizing with
0.2%Triton X-100, coverslips were incubated with primary antibodies.
4′,6-diamidino-2-phenylindole (DAPI) was used for counterstaining
the nuclei, and images were captured using 63 × 1.4 oil differential
interference contrast (DIC) objective of Carl Zeiss Laser Scanning
Microscope LSM 510 Meta and analyzed using LSM Image Browser
(Carl Zeiss). Representative images are shown.
Animal Experiments
All animal experiments were approved by the local ethical
committee and performed according to the guidelines of the German
law of protection of animal life.
Subcutaneous 4T1 Mouse Model
4T1 cells (2 × 106) were subcutaneously injected into the left flank
of 18 female BALB/c mice (Janvier). Nine animals were treated with
either mock [DMSO in phosphate-buffered saline (PBS)] or 5 mg/kgsalinomycin (2 mg/ml in DMSO stock solution was diluted in PBS) on
days 3, 6, 8, 10, 13, and 15. Tumor growth was monitored for 17 days
at indicated time points using a caliper. At the end of the experiment,
mice were sacrificed and tumors were resected for further experiments.
Salinomycin Treatment of SpC-c-MYC Transgenic Mice
All SpC-c-MYCmice were obtained from Chitra Thakur and Ulf R.
Rapp. Animals were genotyped through tail DNA at the age of 3 weeks.
They have similar genetic background (N90% C57Bl/6) and were
maintained heterozygous. Mice developed multifocal hyperplasias and
bronchioloalveolar adenomas and carcinomas derived from alveolar
type II epithelial cells within 10 to 14 months. At the average age of 7
months, mice developed early stages of tumor characterized by
multifocal hyperplasias originating in the alveolar epithelium [21].
A group of 11 SpC-c-MYC mice (72 weeks old) was injected
intraperitoneally every second day with 5 mg/kg salinomycin (2 mg/ml
in DMSO stock solution was diluted in PBS) for 3 weeks. At the end of
the experiment, mice were sacrificed and organs were collected for
further analysis. Mice at the same age from the previous study by Rapp
et al. [22] served as controls.
In Vivo IHC and IF
IHC (hematoxylin and eosin and marker staining) of transgenic lung
tumors and subcutaneous 4T1 tumors as well as IF of 4T1 tumors were
performed as described previously [22] using the primary antibodies
mentioned in the Reagents section. Representative images are shown.
Statistical Analysis
All values are stated as mean ± SD unless otherwise indicated. For
statistical analysis, Student’s t tests were performed (*Pb .5; **Pb .01;
***Pb .001; ****Pb .0001).
Results
Sequential Salinomycin Treatment of MDA-MB-436 Breast
Cancer Cells Leads to Resistance Formation and the Selection
of Epithelial Cell Clones
To induce salinomycin resistance, we used the mesenchymal
breast cancer cell line MDA-MB-436 and sequentially treated the
cells with salinomycin. Each of the four treatment cycles was
followed by a recovery phase until cells were harvested and used for
further experiments. This repeated treatment of MDA-MB-436
cells with salinomycin resulted in a significantly increased
resistance to salinomycin as determined by a cell viability assay
(Figure 1A). Furthermore, the initially high migratory capacity of
the MDA-MB-436 cells was significantly reduced in the salino-
mycin-resistant cells R4 (Figure 1B). Thereby, the cell morphology
of salinomycin-treated cells changed from scattered spindle-shaped
cells to clones growing in clusters with an epithelial-like appearance
(Figure 1C ). When analyzing the expression of the prominent
epithelial and mesenchymal markers E-cadherin and vimentin, we
observed that the mesenchymal expression pattern of these markers
switched to more epithelial-like with an increase of E-cadherin and a
decrease of vimentin (Figure 1, D and E ). Consistent with the
up-regulation of E-cadherin, the expression level of the epithelial
marker miR-200c was significantly increased on salinomycin
treatment (Figure 1F). In addition, we obtained a significant
reduction of zeb2 mRNA, a direct target of miR-200c and an inducer
of epithelial-mesenchymal transition (EMT) in mesenchymal cancer
cells (Figure 1D). Thus, salinomycin treatment of the mesenchymal
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Figure 1. Sequential salinomycin treatment of MDA-MB-436 breast cancer cells leads to resistance formation and the selection of epithelial
cell clones. MDA-MB-436 cells were treated in rounds with 0.05 μM salinomycin followed by a recovery phase until the next round started.
Cells that had received either no (control) or four rounds of treatment (R4) were harvested for the following experiments. (A) Cytotoxicity
assays of sequentially treated MDA-MB-436 cells. Salinomycin-treated (R4) as well as control cells were treated with the indicated
concentrations of salinomycin. Subsequently, cell viability was assessed by the CellTiter-Glo assay. (B) Migratory capacity of control and
salinomycin-treatedMDA-MB-436 cells (R4). Migration was determined by the Boyden chamber assay and the migratory capacity of control
cells was set to one. (C) Microscopic pictures (phase contrast) show the cell morphology of control and salinomycin-treated MDA-MB-436
cells (R4). (D) Quantitative RT-PCR analysis. Relative mRNA levels of the EMT markers E-cadherin, vimentin, and zeb2 were quantified in
control and salinomycin-treatedMDA-MB-436 cells (R4). (E) WB analysis. Total cell lysates of control and salinomycin-treatedMDA-MB-436
cells (R4) were analyzed for the protein expression of E-cadherin and vimentin. (F) miR-200c expression of control and salinomycin-treated
MDA-MB-436 cells (R4). Relative miR-200c levels were determined by quantitative RT-PCR. (G) Cytotoxicity assays of sequentially treated
MDA-MB-436 cells. Salinomycin-treated (R4) as well as control cells were treated with the indicated concentrations of doxorubicin.
Subsequently, cell viability was assessed by the CellTiter-Glo assay.
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like cell clones as characterized by their cell morphology, epithelial
and mesenchymal marker expression, and migratory capacity.Noteworthy, these surviving epithelial-like cell clones were more
resistant to salinomycin treatment and became sensitized to the
classic chemotherapeutic drug doxorubicin (Figure 1G ).
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Turns MDA-MB-436 Cells into Salinomycin-Resistant Cells
Next, we explored whether the acquisition of epithelial traits in the
mesenchymal breast cancer cell line MDA-MB-436 is responsible for
the increased resistance to salinomycin treatment. As miR-200c targetsA B
DC
E
F
Figure 2. MET induced by miR-200c renders MDA-MB-436 cells resi
miR-200c overexpression. Microscopic pictures (phase contrast) sho
(B) Quantitative RT-PCR analysis on miR-200c overexpression in MDA-
vimentin, and zeb2 were quantified. (C) WB analysis on ectopic miR
analyzed for the protein expression of E-cadherin and vimentin. (D) Boy
miR-200c. The number ofmigrated control-transfectedMDA-MB-436 c
ofMDA-MB-436 cells. Control andmiR-200c–overexpressing cells were
the velocity, and the direction ofmovementwere analyzed. (F) Cytotoxic
treated with the indicated concentrations of salinomycin and cell viabizeb1 and zeb2, the transcriptional repressors of E-cadherin, and thereby
determines the epithelial phenotype [23–26], we used this miRNA to
induce mesenchymal-epithelial transition (MET). By ectopically
overexpressing miR-200c in MDA-MB-436 cells (Figure S1), we
obtained a more cobblestone-shaped cell morphology (Figure 2A) andstant to salinomycin. (A) Cell morphology of MDA-MB-436 cells on
w the cell morphology of control and miR-200c–transfected cells.
MB-436 cells. Relative mRNA levels of the EMT markers E-cadherin,
-200c overexpression in MDA-MB-436 cells. Total cell lysates were
den chamber migration assays of MDA-MB-436 cells overexpressing
ells was set to amigratory capacity of one. (E) Time-lapsemicroscopy
monitored using time-lapsemicroscopy. The accumulated distance,
ity assay ofmiR-200c–overexpressingMDA-MB-436 cells. Cellswere
lity was assessed using CellTiter-Glo.
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slightly reduced vimentin levels (Figure 2, B and C ). In addition,
mRNA expression of zeb2, the transcriptional repressor of E-cadherin
and a direct target of miR-200c, was significantly reduced confirming
the miR-200c–induced MET (Figure 2B). Accordingly, we obtained
cells with a lower migratory capacity as determined by Boyden chamber
assay (Figure 2D) and time-lapsemicroscopy. For the latter, we analyzed
the accumulated distance, the velocity, and the direction of the
movement of MDA-MB-436 cells transfected with either miR-200c or
scrambled control (Figure 2E ). Finally, we analyzed MDA-MB-436
cells that overexpress miR-200c in terms of their salinomycin sensitivity
(Figure 2F ). Of note, these cells displaying more epithelial-like
properties were less susceptible to salinomycin treatment. TheseA B
C
E
D
Figure 3. Salinomycin is more effective against cancer cells with mes
breast and lung cancer cell lines. The number of migrated BT-474 cells
were normalized as fold of themigratory capacity of BT-474 cells. (B)mi
levels were determined by quantitative RT-PCR. (C) Correlation between
salinomycin were determined in the panel of breast cancer cells by the
respective cell lines (Pearson r= −0.77). Open circles represent the ep
miR-200c expression and susceptibility to salinomycin. A Pearson co
with the relativemiR-200c expression of the respective cell lines (Pearso
MCF-7. (E) Microscopy of single and co-culturedMCF-7 and/or MDA-M
taken either fromMCF-7,MDA-MB-436, orMCF-7+MDA-MB-436. Nuc
and MDA-MB-436 cells. Co-cultured cells were treated with the indicafindings suggest that the miR-200c–inducedMET as well as a selection
of epithelial-like cell clones may be an important event in the resistance
formation to salinomycin treatment.
Salinomycin Is More Effective against Cancer Cells with
Mesenchymal Traits
As salinomycin resistance is caused by a selection of residual
epithelial-like cells or by the induction of MET by miR-200c, we
investigated whether salinomycin generally affects mesenchymal cancer
cells more effectively than epithelial cancer cells. Therefore, we
characterized several breast and lung cancer cell lines in terms of their
epithelial or mesenchymal phenotypes, i.e., their cell morphology,
epithelial and mesenchymal marker expression, and migratory capacity.F
enchymal traits. (A) Boyden chamber migration assays of different
was set to a migratory capacity of one, and the remaining cell lines
R-200c expression in the different cancer cell lines. RelativemiR-200c
migratory capacity and susceptibility to salinomycin. IC50 values for
CellTiter-Glo assay and correlated with the migratory capacity of the
ithelial cell lines BT-474 and MCF-7. (D) Correlation between relative
rrelation was carried out to compare the sensitivity to salinomycin
n r=0.78). Open circles represent the epithelial cell lines BT-474 and
B-436 cells. IF pictures for E-cadherin (red) and vimentin (green) were
lei were stainedwith DAPI (blue). (F) Treatment of co-culturedMCF-7
ted concentrations of salinomycin (sal) and/or doxorubicin (dox).
Table 1.Migratory Capacity, Relative miR-200c Expression, and Salinomycin Susceptibility in the
Different Cancer Cell Lines
4T1 MDA-MB-436 LLC MDA-MB-231 H1299 MCF-7 BT-474
Migratory capacity 2.31 1.89 1.82 1.82 1.35 1.08 1.00
Relative miR-200c
expression
0.241 0.002 0.000 0.002 0.000 0.807 1.000
IC50 (salinomycin)
[μM]
0.06 0.16 0.36 0.36 0.21 0.47 0.92
The migratory capacity was determined by Boyden chamber assays, the relative miR-200c levels
were determined by quantitative RT-PCR, and the IC50 values for salinomycin were assessed by the
CellTiter-Glo assay using several concentrations of salinomycin.
708 Resistance to Salinomycin Treatment Kopp et al. Translational Oncology Vol. 7, No. 6, 2014The migratory potential of a panel of breast (BT-474, MCF-7,
MDA-MB-231,MDA-MB-436, and 4T1) and lung (H1299 and LLC)
cancer cell lines was determined by Boyden chamber assays (Figure 3A).A
C
E
Figure 4. Salinomycin treatment selects tumor cells with increased epith
growth of subcutaneous 4T1 tumors. 4T1 cells (2×106)were subcutaneo
Animalswere treatedwith eithermock (control) or 5mg/kg salinomycin o
at the indicated time points using a caliper and depicted as tumor volum
sacrificed and tumors were resected. Sections of paraffin-embedded con
hematoxylin and eosin and cleaved caspase 3. (C) WB analysis of 4T1
tumorswere analyzed for the E-cadherin protein expression. (D) IF of 4T1
and vimentin (red). (E)miR-200c expression in 4T1 tumors. RelativemiR-2
determined by quantitative RT-PCR. (mean ± SEM).Accordingly, cell lines with an increased migratory capacity displayed a
high vimentin and, inmost cases, a lowE-cadherin expression on both the
protein and mRNA levels (Figure S2). This was in line with their
mesenchymal spindle-shaped cell morphology (Figure S2). 4T1 cells,
however, displayed high vimentin and significant E-cadherin levels
representing a heterogeneous cell population consisting of mesenchymal
and epithelial cells as determined by IF staining (Figure S3), i.e., cells
that highly express vimentin have rather low levels of E-cadherin and
vice versa. Finally, the expression of miR-200c as a key regulator of EMT
was investigated in the panel of cancer cell lines. In accordance with the
expression of the other markers, miR-200c levels were high in epithelial,
low in mesenchymal, and medium in 4T1 cells (Figure 3B).
To examine the differential sensitivity of these epithelial and
mesenchymal cancer cell lines to salinomycin, the IC50 value for each
cell line was determined and correlated with the respective migratoryB
D
elial marker expression in a syngeneic mouse tumormodel. (A) Tumor
usly injected into the right flank of nine femaleBALB/cmice per group.
n days 3, 6, 8, 10, 13, and 15. Tumor growthwasmonitored for 17 days
e (mm3). (B) IHC of subcutaneous 4T1 tumors. On day 17, mice were
trol and salinomycin-treated tumors were used for IHC and stained for
tumors. Lysates from representative control and salinomycin-treated
tumors. Respective tumor sectionswere stained for E-cadherin (green)
00c levels of salinomycin- andmock-treated (control) 4T1 tumorswere
Translational Oncology Vol. 7, No. 6, 2014 Resistance to Salinomycin Treatment Kopp et al. 709capacity or miR-200c expression as makers for EMT. Thereby,
mesenchymal cell lines with a high migratory potential were rather
sensitive to salinomycin, whereas epithelial cell lines with a lowmigratory
capacity were more resistant to salinomycin (Pearson r= −0.77;
Figure 3C ). Accordingly, miR-200c expression directly correlated with
salinomycin resistance (Pearson r= 0.78; Figure 3D). A numerical table
of the different salinomycin IC50 values, migratory capacities, and
relative miR-200c expression levels is provided in Table 1. These results
emphasize the higher efficacy of salinomycin against mesenchymal
cancer cells. Taking these findings and the increased doxorubicin
sensitivity after salinomycin treatment (Figure 1G ) into account, we
hypothesized that combined treatment of salinomycin and doxorubicin
will have additive effects on heterogeneous tumor cell populations.
We therefore co-cultured the epithelial, non-migratory breast cancer
cell line MCF-7 and the mesenchymal, highly migratory breast
cancer cell line MDA-MB-436. The obtained cell mix roughly
reflects the cellular heterogeneity in tumors, comprising epithelial
and mesenchymal cells as shown by IF staining of E-cadherin and
vimentin (Figure 3E ). Single treatment as well as combinatorial
treatment with doxorubicin and salinomycin revealed a beneficial
effect of the combination confirming the selective efficacy of the
respective drug on the different cell types (Figure 3F ).
Salinomycin Treatment Selects Tumor Cells with Increased
Epithelial Marker Expression in a Syngeneic Mouse Tumor Model
Salinomycin was demonstrated to be effective in different xenograft
mouse tumor models [8,12,14]. Here, we evaluated the potential of
salinomycin to targetmesenchymal cancer cells and thus to induce amore
epithelial-like phenotype in vivo. Therefore, we used the murine breast
cancer cell line 4T1, which per se comprises a heterogeneous cell
population exhibiting both an epithelial (E-cadherin) and amesenchymal
(vimentin) marker expression (Figure S3). 4T1 cells were subcutaneously
injected into BALB/c mice and treated with either salinomycin or mock
(control) every second or third day. A slight effect of salinomycin
treatment on tumor growth was observed (Figure 4A), which can be
explained by an increased apoptosis as determined by IHC of cleaved
caspase 3 (Figure 4B). Of note, consistent with the in vitro results ofA B
Figure 5. Residual tumor cells of an SpC-c-MYC transgenic mouse tum
tumors obtained from tumor-bearing transgenicmice. SpC-c-MYCmice a
every second day. Untreated tumor-bearing SpC-c-MYCmice at nearly th
of tumor-bearing lungs were stained for either (A) E-cadherin, (B) vimentsalinomycin-treated MDA-MB-436 cells, salinomycin-treated tu-
mors displayed elevated E-cadherin protein levels as determined by
WB analysis (Figure 4C). IF staining of untreated 4T1 tumor
sections revealed a heterogeneous cell population consisting of either
E-cadherin–positive or vimentin-positive cells. The latter disap-
peared after salinomycin treatment resulting in an epithelial-like
tumor with considerable E-cadherin expression (Figure 4D),
emphasizing the selective killing of mesenchymal-like cancer cells.
Moreover, miR-200c expression was significantly increased on
salinomycin treatment (Figure 4E ). On the basis of these
observations, we raised the question of whether an up-regulation of
miR-200c was able to inhibit the migration of 4T1 cells as these cells
already display a medium expression of miR-200c. Therefore, we
investigated the migratory capacity of 4T1 cells on miR-200c
overexpression. Boyden chamber assay and time-lapse microscopy
(Figure S4) demonstrated that overexpression ofmiR-200c significantly
reduced the migratory capacity as well as the accumulated distance, the
velocity, and the movement of the miR-200c medium-expressing 4T1
cells, suggesting an additional beneficial effect of salinomycin treatment.
Residual Tumor Cells of an SpC-c-MYC Transgenic Mouse
Tumor Model Display Enhanced Epithelial Marker Expression
To investigate the selectivity of salinomycin treatment on mesenchy-
mal tumor cells in a model based on spontaneous carcinogenesis, we used
the c-MYC–driven transgenic mouse model of non–small cell lung
cancer, which has been previously described by Rapp et al. [22]. The
animals received nine treatmentswith salinomycin every second day. IHC
of salinomycin-treated and control SpC-c-MYC mice displayed an
epithelial-like expression pattern with increased E-cadherin levels on
salinomycin treatment (Figure 5A). Vimentin expression was low and
could not be significantly downregulated (Figure 5B). Consistent with the
syngeneic mouse model, salinomycin-treated lung tumors showed
increased PARP cleavage, indicating augmented apoptosis on treatment
(Figure 5C ). Hence, salinomycin treatment of subcutaneous 4T1 tumors
as well as of transgenic SpC-c-MYC lung tumors led to a selection of
epithelial-like tumor cells, underpinning this resistance mechanism after
long-term application of salinomycin.C
or model display enhanced epithelial marker expression. IHC of lung
t the ageof 72weeks received 12 treatmentswith 5mg/kg salinomycin
e same agewere used as a control group. Paraffin-embedded sections
in, or (C) cleaved Poly(ADP-ribose)-Polymerase (PARP).
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It has been suggested that intratumoral heterogeneity derived from
genetic and non-genetic alterations can remarkably influence clinically
important events, such as metastasis formation and therapy resistance
[27,28]. This implicates that a tumor comprises different cellular
phenotypes, among them migratory, mesenchymal, more chemoresis-
tant cells, as well as non-migratory, epithelial, commonly chemosensi-
tive cells. Developing novel therapeutic strategies for targeting all the
different cell populations within a tumor is crucial for a successful cancer
therapy. Hence, the discovery of the CSC-specific drug salinomycin
raised hope for improved treatment options for patients with cancer by
targeting a chemoresistant subpopulation of tumor cells.
While the occurrence of resistance to classic chemotherapy and
targeted cancer therapies is well described, very little is known about the
resistance formation to salinomycin. Thus, the characterization of the
resistance mechanisms of salinomycin is of particular interest. The
up-regulation of growth factor receptors or prominent cellular survival
pathways is thought to contribute to an enhanced cell survival as an
immediate effect on salinomycin treatment. For instance, the activation of
Akt has been reported as an immediate response to salinomycin treatment
leading to a reduction of salinomycin-induced apoptosis [29]. However,
in contrast to such immediate resistance responses, we report here an
acquired resistance of cancer cells on long-term salinomycin treatment.
We demonstrated that sequential salinomycin treatment resulted in a
selection of epithelial-like cell clones with increased E-cadherin
expression, elevated miR-200c levels, and decreased cell motility. Most
notably, this phenotypic switch was accompanied by an increased
resistance to salinomycin treatment. We furthermore showed that cancer
cells in an epithelial state, i.e., cells with a high epithelialmarker expression
such as miR-200c and a low migratory capability, generally display an
enhanced resistance to salinomycin as compared to mesenchymal cancer
cells. Accordingly, it has been reported that mesenchymal cancer cells are
dedifferentiated and therefore exhibit properties of CSC [30], which are
known to be susceptible to salinomycin treatment. Noteworthy, we
showed that long-term salinomycin treatment resulted in the acquisition
of epithelial traits in the syngeneic 4T1 mouse tumor model and in the
SpC-c-MYC transgenic mouse model for non–small cell lung cancer,
indicating the occurrence of salinomycin resistance also in vivo.
We support the hypothesis that genetic instability and clonal
selection [31] play an essential role in long-term resistance formation
in general. In accordance with this model, long-term salinomycin
treatment determines surviving clones, which exhibit epithelial
properties and are less sensitive to the respective treatment. The
selection of epithelial E-cadherin–positive cells in heterogeneous 4T1
tumors on salinomycin treatment gives further evidence for clonal
evolution as a resistance mechanism. As suggested by recent
publications [32–34], epithelial cells may have a higher capability
than mesenchymal cells to initiate autophagy and thereby to
circumvent salinomycin-induced cytotoxicity, hence explaining the
differential salinomycin susceptibility of these two cell types.
EMT is well known to play a crucial role in tumor progression and
therapy resistance [35]. In particular, the resistance to classic
chemotherapy as well as to targeted therapies, such as gefitinib or
erlotinib, has been ascribed to an induction of EMT in several cancer
types [19,36–38]. Here, we describe the opposite phenomenon of an
increase of epithelial traits on salinomycin treatment. Therefore, this
long-term resistance formation to salinomycin treatment does not
necessarily have to be a disadvantage for cancer therapy. Especially, the
up-regulation of miR-200c represents a favorable effect of salinomycintreatment asmiR-200c hampersmigration andmetastasis by preventing
EMT [23–26,39–41] and modulating migration-relevant target genes
[42,43]. Accordingly, recent studies demonstrated that salinomycin
hampered metastasis formation of lung and breast cancer cells in mice
without significant effects on the primary tumor growth [44,45].
Moreover, it has been shown that an increased expression of miR-200c
improves the susceptibility to classic chemotherapeutics [19,36,46–51]
indicating that acquiring resistance to salinomycin may be beneficial for
the treatment with conventional chemotherapy.
Hence, salinomycin may antagonize tumor progression by reverting
chemotherapy-induced EMT, which is known to be strongly associated
withmetastasis formation and therapy resistance. Salinomycin treatment
thereby leads to less aggressive cancer cells and tumors in terms of lower
migratory capacity, less metastasis, and higher susceptibility to classic
chemotherapy. Salinomycin resistance could therefore become exploited
for conventional cancer therapy in combination with classic chemother-
apy, eventually rendering cancer better controllable.
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